Rodrigo Duterte has hit out at what he called Western threats to seek an International Criminal Court indictment over alleged summary executions.
Alex Tarrant, assistant editor at Dealreporter Europe, weighs in on Johnson & Johnson's proposed acquisition of Swiss biotechnology company Actelion.
Solanezumab, an experimental drug from Eli Lilly, failed to slow the loss of cognitive ability in patients with mild Alzheimer's disease.
Vamil Divan, Credit Suisse senior analyst, discusses Eli Lilly's failed Alzheimer's drug trial and the effect on its stock price.
CNBC's Josh Lipton reports the latest on how some in tech are planning to live a lot longer and thus are experimenting with anti-aging drugs and therapies.
The IOC says the 10, nine of whom hail from former Soviet nations, had all tested positive for various steroids.
At the UCSF Medical Center, a fully automated pharmacy is now filling patient prescriptions.
CNBC's Meg Tirrell on the latest regarding data on how a Puma drug designed to treat breast cancer shows gastric side effects.
CNBC's Bob Pisani looks ahead at what’s moving markets this morning including drugstores.
CNBC's Meg Tirrell reports on drugmaker Eli Lilly responding to tweets from Sen. Bernie Sanders over the price of its Humalog insulin treatment.
Here's why the same old lobbying and crony networks won't help Big Pharma protect its pricing schemes, says Jake Novak.
CNBC's Bertha Coombs reports on the moves in McKesson after its quarterly earnings release.
CNBC's Meg Tirrell speaks to Bristol-Myers CEO Giovanni Caforio about his company's earnings and outlook, August drug trial results, the election and potential M&A.
Opium production in Afghanistan has increased 43 percent in the past year.
CNBC's Meg Tirrell reports the latest on Alkermes' latest depression drug trial.
Jim Cramer is seeing signals that money managers are preparing for a Democratic landslide. He outlines what it could mean for stocks.
Jefferies downgrades Pfizer to hold from buy.
Researchers are working on opioids with all the painkilling power of current drugs but with less risk of addiction or overdose.
Jim Cramer says uncertainty surrounding a Democratic win for the White House puts drug stocks in the danger zone.
The Philippine President's off-the-cuff comments seem like rhetoric but he's made good on promises to target crime and corruption, says Oxford Economics' Oliver Salmon.